Lantern Pharma

Company profile

About Lantern Pharma

Lantern Pharma Inc. is a publicly-traded, clinical-stage biopharmaceutical company focused on transforming oncology drug development through artificial intelligence and precision medicine. The company operates at the intersection of AI, genomics, and machine learning to deliver targeted cancer therapies to the right patients with significantly reduced development costs and timelines. At the core of Lantern's approach is RADR® (Response Algorithm for Drug Positioning & Rescue), a proprietary AI-powered platform that analyzes over 200 billion oncology-specific data points using more than 200 advanced machine learning algorithms. The platform integrates transcriptome data, genomic data, and drug sensitivity information to predict patient responses, identify biomarkers, and stratify patient populations for clinical trials. This data-driven approach enables the company to rescue and revitalize promising oncology compounds while personalizing cancer treatments. Lantern's current portfolio includes three lead drug candidates and an ADC program spanning 12 cancer indications. The company has one lead product candidate (LP-300) in Phase 2 clinical testing through the Harmonic™ trial for never-smoker patients with non-small cell lung cancer, and Phase 1 programs for LP-184 (advanced solid tumors and glioblastoma) and LP-284 (non-Hodgkin's lymphoma). The company has also developed withZeta.ai, an AI research module that unifies clinical, molecular, and therapeutic information for rare and understudied cancers. Lantern Pharma manages an innovative patent portfolio with 95 issued patents and pending applications across 14 patent families.

Company description · Lantern Pharma official website